Kraj: Singapur
Język: angielski
Źródło: HSA (Health Sciences Authority)
DOBUTAMINE HCl EQV DOBUTAMINE
PFIZER PRIVATE LIMITED
C01CA07
12.5 mg/ml
INJECTION
DOBUTAMINE HCl EQV DOBUTAMINE 12.5 mg/ml
INTRAVENOUS
Prescription Only
HOSPIRA INC
ACTIVE
1996-02-05
DOBUTAMINE INJECTION, USP FLIPTOP VIAL R x only MUST BE DILUTED PRIOR TO ADMINISTRATION _DESCRIPTION _ Dobutamine Injection, USP is a clear, practically colorless, sterile, nonpyrogenic solution of dobutamine hydrochloride for intravenous use only. Each milliliter contains 12.5 mg (41.5 µmol) dobutamine, as the hydrochloride and sodium metabisulfite, 0.2 mg added as antioxidant. May contain hydrochloric acid and/or sodium hydroxide for pH adjustment. pH is 3.3 (2.5 to 5.5). Dobutamine Hydrochloride, USP is chemically designated (±)-4-[2-[[3-(ρ-hydroxyphenyl)- 1- methylpropyl] amino]ethyl]- pyrocatechol hydrochloride. It is a synthetic catecholamine. Molecular Weight: 337.85 Molecular Formula: C18H23NO3•HCl _CLINICAL PHARMACOLOGY _ Dobutamine hydrochloride is a direct-acting inotropic agent whose primary activity results from stimulation of the β receptors of the heart while producing comparatively mild chronotropic, hypertensive, arrhythmogenic, and vasodilative effects. It does not cause the release of endogenous norepinephrine, as does dopamine. In animal studies, dobutamine hydrochloride produces less increase in heart rate and less decrease in peripheral vascular resistance for a _ _ given inotropic effect than does isoproterenol. In patients with depressed cardiac function, both dobutamine hydrochloride and isoproterenol increase the cardiac output to a similar degree. In the case of dobutamine hydrochloride, this increase is usually not accompanied by marked increases in heart rate (although tachycardia is occasionally observed), and the cardiac stroke volume is usually increased. In contrast, isoproterenol increases the cardiac index primarily by increasing the heart rate while stroke volume changes little or declines. Facilitation of atrioventricular conduction has been observed in human electrophysiologic studies and in patients with atrial fibrillation. Systemic vascular resistance is usually decreased with administration of dobutamine hydrochloride. Occasionally, minimum vasoconstriction has been Przeczytaj cały dokument